Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

Loss of heterozygosity of TRIM3 in malignant gliomas

Jean-Louis Boulay1, Urs Stiefel2, Elisabeth Taylor1, Béatrice Dolder1, Adrian Merlo1* and Frank Hirth23*

Author Affiliations

1 Department of Biomedicine, University Hospital, CH-4031 Basel, Switzerland

2 Institute of Zoology and Biocenter, University of Basel, CH-4056 Basel, Switzerland

3 MRC Centre for Neurodegeneration Research, King's College London, London, SE5 8AF, UK

For all author emails, please log on.

BMC Cancer 2009, 9:71  doi:10.1186/1471-2407-9-71

Published: 27 February 2009

Abstract

Background

Malignant gliomas are frequent primary brain tumors associated with poor prognosis and very limited response to conventional chemo- and radio-therapies. Besides sharing common growth features with other types of solid tumors, gliomas are highly invasive into adjacent brain tissue, which renders them particularly aggressive and their surgical resection inefficient. Therefore, insights into glioma formation are of fundamental interest in order to provide novel molecular targets for diagnostic purposes and potential anti-cancer drugs. Human Tripartite motif protein 3 (TRIM3) encodes a structural homolog of Drosophila brain tumor (brat) implicated in progenitor cell proliferation control and cancer stem cell suppression. TRIM3 is located within the loss of allelic heterozygosity (LOH) hotspot of chromosome segment 11p15.5, indicating a potential role in tumor suppression. ...

Methods

Here we analyze 70 primary human gliomas of all types and grades and report somatic deletion mapping as well as single nucleotide polymorphism analysis together with quantitative real-time PCR of chromosome segment 11p15.5.

Results

Our analysis identifies LOH in 17 cases (24%) of primary human glioma which defines a common 130 kb-wide interval within the TRIM3 locus as a minimal area of loss. We further detect altered genomic dosage of TRIM3 in two glioma cases with LOH at 11p15.5, indicating homozygous deletions of TRIM3.

Conclusion

Loss of heterozygosity of chromosome segment 11p15.5 in malignant gliomas suggests TRIM3 as a candidate brain tumor suppressor gene.